Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 886-892, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cembrowski, G. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cembrowski, G. S.
Related Collections
Right arrow Laboratory Management
Right arrow Clinical Chemistry Forum
(Clinical Chemistry. 1997;43:886-892.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Thoughts on quality-control systems: a laboratorian's perspective

George S. Cembrowskia

a Address for correspondence: GSC Consulting, 4913 Bruce Ave., Edina, MN 55424. Fax 612-915-1061, e-mail cembr001{at}gold.tc.umn.edu

State-of-the-art prospective quality-control systems entail the use of medically relevant, analyte-specific quality control limits. With analyte-specific limits broader than those generally used in the clinical laboratory, there will be fewer false rejections, fewer unnecessary reanalyses, and shorter delays in run reporting. If the analyte-specific limits are narrower than those used in the laboratory, more errors will be detected, but the user is at risk of identifying errors over which s/he and the manufacturer have little control. The use of various patient data quality-control algorithms is described. Conservatism is stressed in adopting manufacturers' guidelines for surrogate, nondestructive quality-control testing. A simple, optimized approach is suggested for the systematic retrospective review of proficiency data. Finally, an approach is presented for converting from older, previously accepted quality control procedures to more efficient analyte-specific quality control.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
E. Bakker
Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed.
Clin. Chem., April 1, 2006; 52(4): 557 - 558.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. A.R. Bowen, Y. Chan, J. Cohen, N. N. Rehak, G. L. Hortin, G. Csako, and A. T. Remaley
Effect of Blood Collection Tubes on Total Triiodothyronine and Other Laboratory Assays
Clin. Chem., February 1, 2005; 51(2): 424 - 433.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. A. Parvin and A. M. Gronowski
Effect of analytical run length on quality-control (QC) performance and the QC planning process
Clin. Chem., November 1, 1997; 43(11): 2149 - 2154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.